Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A

Jennifer E. Adair,1,2* Devikha Chandrasekaran,1 Gabriella Sghia-Hughes,1 Kevin G. Haworth,1 Ann E. Woolfrey,1,2 Lauri M. Burroughs,1,2 Grace Y. Choi,1 Pamela S. Becker1,2 and Hans-Peter Kiem1,2*

*JEA and H-PK contributed equally to this work.

Fred Hutchinson Cancer Research Center and 1University of Washington School of Medicine, Seattle, WA, USA

ABSTRACT

A hallmark of Fanconi anemia is accelerated decline in hematopoietic stem and progenitor cells (CD34+) leading to bone marrow failure. Long-term treatment requires hematopoietic cell transplantation from an unaffected donor but is associated with potentially severe side-effects. Gene therapy to correct the genetic defect in the patient’s own CD34+ cells has been limited by low CD34+ cell numbers and viability. Here we demonstrate an altered ratio of CD34Hi to CD34Lo cells in Fanconi patients relative to healthy donors, with exclusive in vitro repopulating ability in only CD34Hi cells, underscoring a need for novel strategies to preserve limited CD34+ cells. To address this need, we developed a clinical protocol to deplete lineage+ (CD3 +, CD14+, CD16+ and CD19+) cells from blood and marrow products. This process depletes >90% of lineage+ cells while retaining ≥60% of the initial CD34+ cell fraction, reduces total nucleated cells by 1-2 logs, and maintains transduction efficiency and cell viability following gene transfer. Importantly, transduced lineage− cell products engrafted equivalently to that of purified CD34+ cells from the same donor when xenotransplanted at matched CD34+ cell doses. This novel selection strategy has been approved by the regulatory agencies in a gene therapy study for Fanconi anemia patients (NCI Clinical Trial Reporting Program Registry ID NCI-2011-00202; clinicaltrials.gov identifier: 01331018).

Introduction

Fanconi anemia (FA) is a rare monogenic disease with a wide array and variable presence of clinical symptoms, the hallmark of which is bone marrow (BM) failure.1 The genetic basis of FA is a mutation in any one of 21 genes2 whose protein components make up the FA/breast cancer pathway responsible for DNA repair of interstrand crosslinks through nucleotide excision followed by homologous recombination. Resulting compromises in genetic integrity are associated with a nearly uniform decline in hematopoietic stem and progenitor cells (HSPCs), a 50% incidence of myelodysplastic syndrome or acute myeloid leukemia by adolescence, and a 25% lifetime incidence of head and neck squamous cell carcinoma or gynecological cancer.3 In some patients, blood cell clones demonstrate spontaneous reversion to wild type (i.e. somatic mosaicism) leading to improved and stable blood cell counts for up to 27 years.4-6 Thus, correction of the FA hematopoietic defect could significantly alter the disease’s clinical course, and this has driven decades of research in HSPC gene therapy for FA.

While FA was recognized as an early candidate disorder for gene therapy, several obstacles have been identified that have delayed clinical success.3 Initial clinical trials demonstrated a dramatic approximately 50-fold reduction in the number of true HSPCs in FA patients relative to other gene therapy patients, such as those treated for primary immune deficiencies.7 Moreover, FA HSPCs were exceptionally fragile when manipulated ex vivo for gene transfer. No treated patient has demonstrated...
stable improvements in blood cell counts with long-term persistence of gene-corrected blood cells. These studies highlighted two needs for innovation in FA gene therapy: 1) to increase the number of available HSPCs for gene transfer and infusion, and 2) to increase the engraftment potential of these cells after gene transfer and infusion. Following the recommendations of the International FA Gene Therapy Working Group, we launched a phase I clinical trial of gene therapy for FA complementation group A (FA-A) patients in 2011 (clinicaltrials.gov identifier: NCT01331018). This trial design incorporates several features aiming to improve HSPC numbers and fitness. These include: i) a self-inactivating (SIN) lentiviral vector (LV) for transfer of the FANCA cDNA regulated by a human phosphoglycerate kinase (hPGK) promoter; ii) a short, overnight transduction to minimize ex vivo manipulation, as well as addition of the antioxidant N-acetylcysteine (NAC) throughout manipulation; and iii) culture under reduced oxygen (5%) to limit oxidative DNA damage.9

The target HSPC population for gene transfer expresses the CD34 cell surface protein (CD34+). When stained with fluorophore-conjugated antibody against CD34 and analyzed by flow cytometry, a small proportion of BM cells are CD34+, representing both primitive stem cells and more committed progenitors.10 The standard clinical procedure for isolating these cells first involves either BM collection or mobilization of the cells into circulation through cytokine stimulation with granulocyte colony stimulating factor (G-CSF) or, in certain clinical scenarios, a combination of G-CSF and the chemokine receptor CXCR4 antagonist plerixafor, followed by peripheral blood leukapheresis (mAPH). Initial isolation technologies relied on the CD34 antigen expression on the cell surface and utilized biotinavidin affinity, panning, or immunomagnetic bead-based approaches. Expected yields were 50% of available CD34+ cells with highly variable purities, ranging from 20-90% across techniques.11 Of these, immunomagnetic bead-based positive selection is the most widely-applied today, with the first US Food and Drug Administration (FDA) approval of a clinical device for human use in 2014. Advances in this technology to include automation have improved reliability in recovery to a mean yield of 70% with purities regularly over 90%.12,13 Of these, immunomagnetic bead-based positive selection is the most widely-applied today, with the first US Food and Drug Administration (FDA) approval of a clinical device for human use in 2014. Advances in this technology to include automation have improved reliability in recovery to a mean yield of 70% with purities regularly over 90%.12,13 Of these, immunomagnetic bead-based positive selection is the most widely-applied today, with the first US Food and Drug Administration (FDA) approval of a clinical device for human use in 2014. Advances in this technology to include automation have improved reliability in recovery to a mean yield of 70% with purities regularly over 90%.12,13 Of these, immunomagnetic bead-based positive selection is the most widely-applied today, with the first US Food and Drug Administration (FDA) approval of a clinical device for human use in 2014. Advances in this technology to include automation have improved reliability in recovery to a mean yield of 70% with purities regularly over 90%.12,13 However, these values are based on BM and mAPH products wherein 1-3% of total cells express CD34 antigen, and the majority of these cells display high levels of CD34. For FA patients, the frequency of CD34+ cells is much lower: 0.1-1.5% in BM.14,15 This implies that non-standard processes may be required to preserve the limited numbers of HSPCs for gene transfer in FA.

Here we report HSPC collection results for the first 3 patients treated on our study. Initially, this protocol proposed direct isolation of CD34+ cells from BM without prior attempts at mobilization. The addition of a mobilization regimen with subsequent leukapheresis collections has permitted the evaluation of CD34 expression patterns in both product types and provided evidence for the need for alternative HSPC isolation strategies.

**Methods**

**Patient selection**

This study was approved by an Institutional Review Board at Fred Hutchinson Cancer Research Center (Fred Hutch) in accordance with the Declaration of Helsinki and the FDA, and conformed to the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules. Informed consent was obtained from all patients or guardians. FA patients aged 4 years or over were diagnosed by a positive test for increased sensitivity to chromosomal breakage with mitomycin C (MMC) or diepoxybutane. Correction of melphalan hypersensitivity following retroviral transduction of the FANCA cDNA identified Patient 3 as belonging to the FA-A complementation group. (Online Supplementary Table S1). FA-A patients who demonstrated normal karyotype in BM analyses as defined in the trial were considered eligible for the study. Characteristics of enrolled patients are available in Table 1.

**Lentiviral vectors**

All SIN lentiviral (LV) vectors were produced with a third-generation split packaging system and pseudotyped with vesicular stomatitis virus glycoprotein (VSVG) using infectious clone (pRSC-PGK.VSVG.eGFP) or the full-length FANCA cDNA (pRSC-PGK.FANCA-sW), both regulated by an hPGK promoter. Research-grade vectors were produced by the Fred Hutch Vector Production Core (Principal Investigator: HPK). Clinical-grade LV (pRSC-PGK. FANCA-sW), was produced by the Indiana University Vector Production Facility (IUVPF, IN, USA) using a large-scale, validated process following Good Manufacturing Practices standards under an approved Drug Master File held by IUVPF. Infectious titer was determined by serial transduction of HT1080 human fibrosarcoma-derived cells and evaluated either by flow cytometry for eGFP expression or by quantitative polymerase chain reaction (qPCR).

---

### Table 1. Clinical characteristics of 3 patients with Fanconi Anemia A genetic defect enrolled in clinical trial NCT01331018.

| Patient | Age (years) | Weight (kg) | Sex | Baseline ANC/platelet count (thousand/μL) | Marrow cellularity | FANCA defect |
|---------|-------------|-------------|-----|------------------------------------------|-------------------|-------------|
| 1       | 22          | 70.7        | Male | 1.3/65                                   | 10-30%            | Exon22 splice variant (c. 1827-1 G>A) |
| 2       | 10          | 19.6        | Male | 1.0/62                                   | ~20%              | Exons6-31    |
| 3       | 5           | 14.7        | Male | 1.7/32                                   | ~30%              | Not determined |

One adult and 2 pediatric patients were treated with lentivirus gene therapy for Fanconi Anemia A (FA-A) defect. Three patients demonstrated steadily declining absolute neutrophil count (ANC) and platelet counts in the peripheral blood prior to treatment and less than 30% marrow cellularity. Molecular characterization of the FANCA gene defect performed by gene sequencing demonstrated that Patient 1 was homozygous in the FANCA gene for the splicing variant. For Patient 2, Multiplex Ligation-dependent Probe Amplification (MLPA) on the FANCA gene identified a homozygous gross deletion of exons 6-31. No sequence analysis was performed for Patient 3, but complementation testing confirmed FANCA defect.
at 37°C, 5% CO2 and 5% O2, cells were harvested for infusion. 10 infectious units (IU)/cell. Following 12-24 hours of incubation, the cells were transduced at a multiplicity of infection (MOI) of 5-10 (Cumberland Pharmaceuticals, Nashville, TN, USA). Cells were also transduced using lentiviral vectors from CellGenix GmbH, Freiburg, Germany, and 1 mM NAC.

Thrombopoietin (rhTPO) and Flt-3 ligand (rhFLT3L) (all from Miltenyi Biotec GmbH) were included in the media (StemCell Technologies, Vancouver, BC, Canada), supplemented with 4 μg/mL of protease inhibitors (American Pharmaceutical Partners; APP, East Shaumburg, IL, USA), and 1 mM NAC.

CD34⁺ high CD34 expression; CD34⁺ low CD34 expression; BM: bone marrow product; mAPH: mobilized apheresis product.

### Study design and HSPC isolation

Patients underwent either BM harvest with a target collection goal of 15 cc/kg body weight or were administered daily G-CSF (filgrastim; 16 μg/kg BID; days 1-6) and plerixafor (240 μg/kg/day; days 4-6) subcutaneously to mobilize CD34⁺ cells. Mobilized patients were subjected to large volume leukapheresis when circulating CD34⁺ blood cell counts were ≥5 cells/μL. Healthy donor blood products were purchased from a commercial source (BM products; StemExpress, Folsom, CA, USA) or institutional shared resources (mAPH products). Immunomagnetic beads were from Miltenyi Biotec, GmbH (Auburn, CA, USA). For BM products, RBC were debulked by hetastarch sedimentation prior to labeling. Custom programming for lineage depletion was designed and executed on the CliniMACS Prodigy™ device (Miltenyi Biotec GmbH, Germany). For mAPH products, an initial platelet wash was performed prior to labeling. Custom programming for lineage depletion was designed and executed on the CliniMACS Prodigy™ device (Miltenyi Biotec, GmbH). Complete processing methods are included in the Online Supplementary Materials and Methods.

### Transduction

CD34⁺-enriched cells were cultured on RetroNectin™ (Takara Bio, Mountain View, CA, USA)-coated culture flasks at a density of 1x10⁶ cells/mL and 2.9x10⁵ cells/cm² in StemSpan™ ACF media (StemCell Technologies, Vancouver, BC, Canada), supplemented with 4 μg/mL of protease inhibitors (American Pharmaceutical Partners; APP, East Shaumburg, IL, USA), 100 ng/mL each of recombinant human stem cell factor (rhSCF), thrombopoietin (rhTPO) and Flt-3 ligand (rhFLT3L) (all from CellGenix GmbH, Freiburg, Germany), and 1 mM NAC (Cumberland Pharmaceuticals, Nashville, TN, USA). Cells were immediately transduced at a multiplicity of infection (MOI) of 5-10 infectious units (IU)/cell. Following 12-24 hours of incubation at 37°C, 5% CO₂ and 5% O₂, cells were harvested for infusion and/or analyses.

### Transplantation in NSG mice

All animal work was performed under protocol 1864 approved by the Fred Hutch Institutional Animal Care and Use Committee. NOD.Cg-PrkdcscidIl2rgmT1/2tm2Sj (NOD/SCID/IL2rg⁻⁻, NSG) mice were housed at Fred Hutch in pathogen-free conditions approved by the American Association for Accreditation of Laboratory Animal Care. 8-12-week old mice received 275 cGy total body irradiation (TBI) from a Cesium source. Four hours after TBI, 1x10⁶ gene-modified total nucleated cells (TNCs) re-suspended in 200 μL phosphate buffered saline (D-PBS, Life Technologies Corporation, Grand Island, NY, USA) containing 1% heparin (APP) were infused via the tail vein. Blood samples were collected into ethylenediaminetetraacetic acid (EDTA) Microtainers (BD Bioscience, San Jose, CA, USA) by retro-orbital puncture and diluted 1:1 with PBS prior to analysis. At necropsy, spleen and BM were collected. Tissues were filtered through 70 μm mesh (BD Bioscience) and washed with Dulbecco’s PBS (D-PBS).

### Colony-forming cell assays

Transduced cell products were seeded in standard CFC assays in methylcellulose media (H4230, Stem Cell Technologies) as previously described with the following exceptions: to assess FANCA gene function, MMC (Sigma Aldrich, St. Louis, MO, USA) was added at concentrations of 0 nM, 5 nM, 10 nM, or 20 nM. Complete colony DNA extraction and PCR methods are included in the Online Supplementary Materials and Methods.

### Quantitative real-time PCR-based measurement of vector copy number

Vector copy number (VCN) per genome equivalent was assessed by TaqMan 5' nuclease quantitative real-time PCR assay in duplicate reactions with an LV-specific primer/probe combination (forward, 5'-TGAAGCGAAGGGAACCA;
reverse, 5'-CCGTGCGCGCTTCAG; probe, 5'-AGCTCTCTCGACGCAGGACTCGGC (Integrated DNA Technologies; IDT, Coralville, IA, USA) and in a separate reaction with a β-globin-specific primer/probe combination [forward, 5'-CCTATCAGAAAGTGGTGGCTGG; reverse, 5'-TTGGACAGCAAGTGAGCTT; probe, 5'-TGGCTAATGCCCTGGCCA-CAAGTA (IDT)]. Two standard curves were established by serial dilution of gDNA isolated from a human cell line (HT1080) confirmed to contain a single integrant of the same LV backbone and from peripheral leukocytes collected from a healthy donor using both primer-probe sets independently.

Individual colony gDNA samples were subjected to multiplex real-time TaqMan qPCR to amplify the LV-specific product and an endogenous control (TaqMan Copy Number Reference assay RNaseP, Thermo Fisher Scientific, Pittsburgh, PA, USA). Samples with an average VCN \( \geq 0.5 \) were considered transduced.

Flow cytometry analysis of hematopoietic subsets

Stained cells were acquired on a FACSCanto™ II, FACSaria™ II or FACS LSR II (all from BD Bioscience) and analyzed using FlowJo software v.10.0.8 (Tree Star Inc., Ashland, OR, USA). Analysis was performed on up to 20,000 cells. Gates were established using Full Minus One stained controls.

Antibodies included anti-human CD34 (clone 563), CD16 (clone 3G8), CD3 (clone UCHT1), CD4 (clone L200), CD8 (clone RPA-T8), all from BD Biosciences; CD14 (clone 61D3), Thermo Fisher Scientific, Pittsburgh, PA, USA; CD19 (clone 4G7), BD Pharmingen, San Diego, CA, USA; CD90 (clone 5E10), CD20 (clone 2H7), CD15 (clone W6D3), all from Biologend (San Diego, CA, USA); CD133 (clone 293C3), Miltenyi Biotec, GmbH; CD45 (clone D058-1283) and CD45RA (clone 5H9), both from BD Horizon (San Jose, CA, USA).

For mouse samples, antibodies were anti-mouse CD45-V500 (561487, clone 30-F11), anti-human CD45-PerCP (547464, clone 2D1), CD3-FITC (555382, clone UCHT1), CD4-V450 (560845, clone RPA-T4), CD6-APC-Cy7 (557834, clone SK1), CD20-PE (555623, clone 2H7), and CD14-APC (555824, clone 5B1), all from BD Biosciences.

Results

Diminished CD34\(^{\text{hi}}\) expressing cells in FA-A BM and mAPH

Two enrolled patients underwent BM harvest to collect available CD34\(^{+}\) HSPCs (Patients 1 and 2). The third patient underwent mobilization with filgrastim and plerixafor followed by peripheral blood leukapheresis (Patient 3). All 3 patients demonstrated reduced CD34 expression and estimated numbers of CD34\(^{+}\) cells in screening BM aspirate samples prior to collection and treatment, relative to healthy donor BM products, as well as in cell products collected for CD34\(^{+}\) cell isolation and gene transfer (Figure 1). Two levels of CD34 expression were observed, CD34\(^{\text{lo}}\) [mean fluorescence intensity (MFI)=3453±516] and CD34\(^{\text{hi}}\) (MFI=19731±4103). Notably, the proportion of CD34\(^{\text{hi}}\) cells were markedly reduced in FA-A patients relative to those observed in healthy donors (Figure 1).

FA-A CD34\(^{\text{hi}}\) cells, but not CD34\(^{\text{lo}}\) cells, demonstrate \textit{in vitro} repopulating capacity

To determine which CD34\(^{+}\) cells demonstrated repopulation potential, we used colony-forming cell (CFC) potential as a surrogate. This required sufficient blood product to flow-sort CD34\(^{+}\) and CD34\(^{\text{hi}}\) cells for \textit{in vitro} assays. Only the mAPH product collected from Patient 3 was sufficient for this study. For direct comparison, we sort-purified CD34\(^{\text{lo}}\) and CD34\(^{\text{hi}}\) cells from a healthy donor mAPH product. Only CD34\(^{\text{hi}}\) cells from the FA-A patient demonstrated colony-forming potential (Figure 2A). In the healthy donor, CD34\(^{\text{hi}}\) cells also demonstrated the majority of CFC capacity in comparison with CD34\(^{\text{lo}}\) cells, and at much higher levels as compared to the FA-A patient (Figure 2B). These data suggest repopulating capacity is restricted to CD34\(^{\text{hi}}\) cell fractions, underscoring the need to preserve as many of these cells as possible for gene transfer processes.
Extensive loss of FA-A CD34⁺ cells with direct clinical purification protocols

The current clinical standard for CD34⁺ cell enrichment is optimized for collection of CD34⁺ cells. However, in Patient 1, direct enrichment of CD34⁺ cells using this protocol was inefficient, resulting in an approximately 3% yield and only 5.34×10⁶ total CD34⁺ cells available for gene transfer (Table 2). Moreover, the purity of the enriched cell product was only 58.9%, and approximately 47% loss in viable cells was observed during culture and gene transfer. Resulting gene-modified cells retained colony-forming capacity and demonstrated acquired resistance to the potent DNA crosslinking agent MMC following LV-mediated FANCA gene transfer (Table 3).

In Patient 2, estimated losses during direct CD34 enrichment and gene transfer were expected to reduce the cell product available for transduction to a level lower than observed for Patient 1. Thus, an urgent amendment was filed with the FDA to permit elimination of the direct CD34 enrichment steps and allow transduction of the entire red blood cell (RBC)-depleted BM product. This processing change preserved more CD34⁺ cells (Table 2), with improved transduction and viability (Table 3). Together, these data suggested that minimal manipulation of target CD34⁺ cells from FA-A patients could improve yield, gene transfer efficiency, and function in vivo.

Development of a novel strategy to deplete lineage- cells

We hypothesized that depleting non-target mature B cells, T cells, monocytes, and granulocytes would retain precious CD34⁺ cells with minimal manipulation, since CD34-expressing cells would not be directly labeled, selected, or washed (Figure 3). Building on our previous work automating cell selection and gene transfer using the Clinimacs Prodigy™ device, we designed a customized, automated RBC debulking and immunomagnetic bead-based lineage specific depletion strategy (Online Supplementary Materials and Methods). Four different bead-conjugated antibody reagents were used in this approach: anti-CD3 (T-cell removal), anti-CD14 (monocyte removal), anti-CD16 (granulocyte and NK-cell removal), and anti-CD19 (B-cell removal). This protocol was designed for both BM and mAPH products.

Lineage depletion preserves available CD34⁺ cells for gene transfer

A total of nine BM and ten mAPH products were processed to establish process validity. An average 60% of BM CD45⁺ cells and 50% of mAPH CD45⁺ cells expressed one of the four target markers (CD3, CD14, CD16, or CD19) (Online Supplementary Figure S1A and B, respectively). CD34⁺ cell content in these products ranged from 0.35-1.4% in BM and 0.06-0.9% in mAPH products. The average process run time for BM products was ten hours, whereas mAPH products were processed over 13 hours. Observed total nucleated cell (TNC) reduction was approximately 1 log for both BM and mAPH products following lineage depletion (Figure 4A). All target lineage- cells were depleted to less than 10% of initial numbers, and CD34⁺ cells were retained at 94.62±4.61% for BM products and 70.69±11.4% for mAPH products (Figure 4B). Retention of available CD34⁺ and CD34⁻ cells was observed and comparable or superior to that observed for the same products by direct CD34-enrichment (Online Supplementary Figure S2). Approximately 24% of BM CD34⁺ cells were colony-forming in a standard methylcellulose assay, while 51% of mAPH CD34⁺ cells formed colonies (Figure 4C and Online Supplementary Figure S3). However, following LV transduction of these cells using the same protocol proposed for FA-A patient cells, we observed consistent 50% rates of gene transfer into CFCs from both cell product types (Figure 4D). Analysis of single colonies demonstrated an average VCN per CFC of 0.7 for BM CD34⁺ cells and 1.6 for mAPH CD34⁺ cells. VCN was also assessed in bulk transduced cells cultured for ten days in vitro, demonstrating an average value of 5 for both BM and mAPH products (Figure 4E). Final cell products tested for mycoplasma and sterility were negative, and endotoxin testing demonstrated values within criteria for patient infusion. Lineage-depleted and transduced cells from six mAPH and BM products each were infused into immunodeficient (NSG) mice at a target cell dose of 1×10⁶ TNC per mouse. On average, the CD34⁺ cell dose per mouse for BM products was 2.86±1.0 CD34⁺ cells [standard error of the mean (SEM)=6.67±10⁶] and for mAPH products was 1.08±10⁶ CD34⁺ cells (SEM=1.45±10⁶). Flow cytometry analysis on peripheral blood was used to evaluate engraftment (human CD45⁺ and lineage development into T cells (human CD3⁺), B cells (human CD20⁺),
and monocytes (human CD14⁺) over time (Figure 4F). Both mAPH and BM products demonstrated long-term engraftment over 20 weeks of monitoring. Engraftment levels were comparable to results reported by Wiekmeijer et al. with CD34⁺ cells purified from BM and infused at similar cell doses.¹⁸

**Lineage-depleted cell products xenoengraft equivalently to CD34-enriched products**

In this experiment, healthy donor BM products were divided into two aliquots. One was lineage-depleted and the other CD34-enriched. Resulting cell populations were transduced with the same LV vector under identical conditions and infused into NSG mice at matched CD34⁺ cell doses. We observed higher CD34⁺ cell retention with lineage depletion compared to CD34 selection, with no differences in transduction efficiency or colony-forming potential (Figure 5A and B). We observed slightly higher, but not significantly different, levels of human CD45⁺ blood cell engraftment in mice receiving transduced, lineage-depleted cells relative to mice receiving CD34-selected cells. We also observed more stability of T- and B-cell engraftment in mice receiving lineage-depleted cell products relative to mice receiving CD34-selected cell products (Figure 5C).

**Lineage depletion protocol preserves limited FA CD34⁺ cells**

These data collectively suggest that lineage-specific depletion preserved available CD34⁺ cells without compromising transduction efficiency or cell fitness. Under FDA approval, the clinical protocol was modified to include both BM and/or mAPH products, with lineage depletion as the method of CD34⁺ cell enrichment. Patient 3 (the first treated under the modified protocol) was a 5-year-old male with FA-A confirmed by complementation studies. Baseline neutrophils averaged 1.7x10⁹/L and baseline platelets averaged 32x10⁹/L in the six months prior to treatment, with declining neutrophils and platelets over the prior 2-year interval (Online Supplementary Figure S4). Mobilization of ≥10 CD34⁺ cells/mL peripheral blood was achieved (Online Supplementary Figure S5A), and two successive apheresis collections resulted in 8.5x10¹⁰ TNC containing a total 1.6x10⁹ CD34⁺ cells (Table 2). The patient required a total of two platelet transfusions and two packed red blood cell transfusions during mobilization and leukapheresis (Online Supplementary Figure S5B). Due to column limitations, 5x10¹⁰ TNC (equivalent to 9.5x10⁷ total CD34⁺ cells) were subjected to lineage depletion, and the remainder were cryopreserved. Lineage depletion resulted in a 94% reduction in TNC and a 56% retention of available CD34⁺ cells. CD34 purity was 1.6%, representing a 1-2 log-fold increase in the total number of CD34⁺ cells per kg available for transduction and infusion relative to Patients 1 and 2 (Table 2). A total of 52.8x10⁶ CD34⁺ cells were transduced at an MOI of 5 IU/cell, resulting in a final cell dose of 2.4x10⁶ total CD34⁺ cells per kg with 99.3% viability based on trypan blue dye exclusion. Approximately 26% of CFCs in this cell product were transduced, displaying a mean VCN of approximately 1 (0.9) (Table 3). Thus, limited numbers of available CD34⁺ cells were indirectly enriched using lineage deple-

---

**Figure 3. Direct CD34 enrichment versus depletion of lineage positive (+) cells.** Products can include bone marrow (BM) or mobilized apheresis product (mAPH) (1). BM products were first processed through hetastarch sedimentation to deplete red blood cells (RBCs). Leukapheresis products were first subjected to several washes to deplete platelets. For direct CD34⁺ cell selection, anti-CD34 antibody-bound immunomagnetic beads (microbeads) are used, whereas for lineage depletion anti-CD3; CD14; CD16; and CD19; microbeads are used (2). In both cases, microbead-bound cells are retained on the column and subjected to wash steps. When lineage depletion is used, CD34-expressing cells undergo minimal manipulation during purification. Following purification, cells are cultured and transduced with a VSV-G pseudotyped lentiviral vector at a multiplicity of infection (MOI) of 5–10 IU/ cell (3). Following ~16 hours of incubation cells are harvested (4). *These processes were performed on the CliniMACS Prodigy™ device from Miltenyi Biotec GmbH.
Discussion

Here we confirm prior reports of inefficient CD34+ cell enrichment from FA patient blood products by direct, immunomagnetic bead-based separation, which is the current standard protocol for isolating HSPCs.15,19-21 We also demonstrate substantially reduced levels of CD34+ cells in FA patients relative to healthy donors, which likely contributes to poor positive selection results in blood products from FA patients. Colony seeding assays demonstrate that only CD34+ cells contribute to in vitro colony-forming potential in both FA and healthy donor blood products, underscoring the need to preserve as many available CD34+ cells as possible during ex vivo manipulation for gene transfer. We demonstrate a clinically viable procedure for depleting lineage positive cells to indirectly enrich for CD34+ cells that preserves the limited numbers of these cells in FA patients without compromising viability, gene transfer, or engraftment potential.

Importantly, the phenotype of limiting CD34+ cell numbers is not restricted to FA alone. Sickle cell disease (SCD) patients treated with hydroxyurea also display reduced CD34+ cell frequencies in BM, and there is a contraindication to mobilization of available CD34+ cells owing to an increased risk of vaso-occlusive crisis.22 Other inherited BM failure syndromes such as dyskeratosis congenita also are associated with abnormal CD34+ cell frequencies and behavior.23 As a larger number of disease targets become relevant for gene therapy, additional patient populations will likely display variable CD34+ cell frequency and antigen expression. These disease targets could also benefit from clinically viable alternative selection procedures such as we have developed here.

Our observation of CFC potential in only the CD34+ fraction in both FA and healthy samples suggests that CD34+ cells may not be contributing to hematopoietic reconstitution. Notably, our data are from mAPH samples not BM, and we will need more patients for confirmation. Additionally, the standard colony-forming assay best defines progenitor cells, more so than true long-term repopulating hematopoietic stem cells.24 Alternatively, xenotransplant of purified cells into immunodeficient mice could provide the most robust evidence for CD34+ cell function in vivo, but the very small numbers of these cells may prove problematic to achieving relevant cell doses needed for these experiments. Another in vitro assay, such as the long-term culture-initiating cell assay,25 may provide additional insight into the desired target CD34+ subpopulations for gene therapy if they are present in either the CD34+ or CD34+ populations in FA patients. In this regard, we recently demonstrated that the CD34+CD45RA CD90- phenotype is responsible for hematopoietic repopulation in non-human primates in the autologous, myeloablative setting,12 and evaluation of this phenotype in the enrolled FA patients is ongoing. Critically, our strategy of depleting cells expressing mature
blood cell lineage markers preserves all CD34+ cell phenotypes for gene transfer and infusion, as demonstrated by Patient 3, whose infused CD34+ cell dose was the largest received to date.

One characteristic of lineage-depleted cell products requiring additional study is the presence and impact of other supporting cells on engraftment. Especially for BM-derived products, our procedure does not include a marker to deplete mesenchymal stem cells (MSC). While the engraftment potential of MSC manipulated ex vivo in CD34+ cell supportive media is unexplored, two recent reports suggest that these cells are integral to BM function in FA, and can be LV-transduced and functionally corrected to facilitate hematopoietic recovery and function in a mouse model of FA.\(^26,27\) For mAPH-derived products, such as that infused into Patient 3, additional follow up will be required to determine if a selective advantage is observed in vivo. The improved transduction efficiency of lineage-depleted cell products could reflect non-repopulating CD34- cell uptake of LV. However, we still observed a benefit in transduction of hematopoietic CFC, even at the lower MOI of 5 IU/cell. One other possible explanation is the age and clinical condition of Patient 3. To address this concern we compared our results in Patient 3 to the 4 FA patients enrolled in the FANCOSTEM clinical trial in Spain (clinicaltrials.gov identifier: 02931071).\(^28\) These 4 patients were aged 3-7 years and demonstrated higher baseline blood cell counts at the time of collection. All 4 patients received the same mobilization regimen as Patient 3 reported here, but resulting mAPH products were subjected to direct CD34 enrichment prior to transduction at an MOI of 100 IU/cell. The reported mean VCN was 0.4±0.1 and ranged from 0.1 to 0.4 copies in individual CFC. Our data with a higher VCN at lower MOI, as shown in Figure 5, suggests that lineage-depleted cell products are a viable alternative for gene transfer in FA.
MOI suggest that the mixed cell culture supports transduction of hematopoietic progenitor cells, at least.

In conclusion, we describe an alternative strategy to a direct, immunomagnetic bead-based selection of CD34-expressing cells that overcomes current barriers in isolation of blood stem and progenitor cells especially for diseases like FA. Our novel approach to preserve available CD34+ cells during initial blood product processing has the potential to improve gene therapy and gene editing in settings of limited CD34+ cell availability, including FA and other diseases in which direct CD34 enrichment has proven inefficient, such as SCD.

Acknowledgments
We thank our patients and their families. We thank the Fanconi Anemia Research Fund for sponsoring patient travel and housing arrangements associated with this study. We especially thank the Fred Hutch Cell Processing Facility and Seattle Cancer Care Alliance for their support in enrollment and treatment of clinical trial patients. We thank H. Crawford and K. Gonzalez for help in preparing the manuscript.

We declare that they have no competing interests.

References
1. Nalepa G, Clapp DW. Fanconi anemia and cancer: an intricate relationship. Nat Rev Cancer. 2018;18(5):168-185.
2. Mamrak NE, Shimamura A, Howlett NG. Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia. Blood Rev. 2017;31(3):95-99.
3. Adair JE, Sevilla J, Heredia CD, Becker FS, Kiem HP, Bueren J. Lessons learned from two decades of clinical trial experience in gene therapy for Fanconi anemia. Curr Gene Ther. 2017;16(5):358-348.
4. Asur RS, Kimble DC, Lach FP, et al. Somatic mosaicism of an intragenic FANCB duplication in both fibroblast and peripheral blood cells observed in a Fanconi anemia patient leads to milder phenotype. Mol Genet Genomic Med. 2016;4(6):77-91.
5. Gregory JJ, Jr., Wagner JE, Verlander PC, et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci USA. 2001;98(5):2532-2537.
6. Mankad A, Taniguchi T, Cox B, et al. Natural gene therapy in monozygotic twins with Fanconi anemia. Blood. 2006;107(8):3084-3090.
7. Verhoeyen E, Roman-Rodriguez HJ, Cosset F, Levy C, Roo P. Gene therapy in Fanconi anemia: A matter of time, safety and gene transfer tool efficiency. Curr Gene Ther. 2017;16(5):297-308.
8. Tolar J, Adair JE, Antoniou M, et al. Stem cell gene therapy for Fanconi anemia: report from the 1st International Fanconi Anemia Gene Therapy Working Group meeting. Mol Ther. 2011;19(7):1193-1198.
9. Becker FS, Taylor JA, Trobridge GD, et al. Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. Gene Ther. 2016;17(10):1244-1252.
10. Syrjala M, Ruutu T, Jansson SE. A Blow cytometric assay of CD34-positive cell populations in the bone marrow. Br J Haematol. 1994;88(4):679-684.
11. Collins RH Jr. CD34+ selected cells in clinical transplantation. Stem Cells. 1994;12(6):577-585.
12. Spohn G, Wiercinska E, Karpova D, et al. Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. Cytotechnology. 2015;71(5):1465-1471.
13. Aversa ST, Goss C, Bleau S, Tonon JA, Meagher RC. How do I perform hematopoietic progenitor cell selection? Transfusion. 2016;56(5):1008-1012.
14. Muller LU, Williams DA. Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia (Review). Mutat Res. 2009;668(1-2):141-149.
15. Kelly FF, Radtke S, von Kalle C, et al. Stem cell collection and gene transfer in Fanconi anemia. Mol Ther. 2007;15(1):211-219.
16. Radtke S, Adair JE, Giese MA, et al. A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates. Sci Transl Med. 2017;9(414).
17. Adair JE, Waters T, Havistrict K, et al. Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun. 2016;7:13175.
18. Wiekmiejer AS, Pike-Overtzet K, Brugman MH, et al. Sustained engraftment of cytokine-primed human bone marrow CD34+ cells in young adult NSG mice. Biorex Open Access. 2014;3(5):110-116.
19. Liu JM, Kim S, Read EJ, et al. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther. 1999;10(14):2387-2396.
20. Croop JM, Cooper R, Fernandez C, et al. Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. Blood. 2001;98(10):2917-2921.
21. Langheimo J, Marolleau JP, Soulier J, et al. Hematopoietic progenitor cell harvest and functionality in Fanconi anemia patients. Blood. 2002;100(8):3051.
22. Uchida N, Fujita A, Hsieh MM, et al. Bone marrow as a hematopoietic stem cell source for gene therapy in sickle cell disease: Evidence from rhesus and SCD patients. Hum Gene Ther Clin Dev. 2017;28(5):136-144.
23. Balakumaran A, Mishra PJ, Paweleczak E, et al. Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders. Blood. 2015;125(5):793-802.
24. Coulombel L. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene. 2004;23(43):7210-7222.
25. Miller CL, Eaves CJ. Long-term culture-initiating cell assays for human and murine cells. Methods Mol Med. 2002;63:123-141.
26. Jacome A, Navarro S, Roo E, et al. Lentiviral-mediated genetic correction of hematopoietic- and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther. 2009;17(6):1083-1092.
27. Zhou Y, He Y, Xing W, et al. An abnormal bone marrow microenvironment contributes to hematopoietic dysfunction in Fanconi anemia. Haematologica. 2017;102(6):1017-1027.
28. Roo E, Navarro S, Gueenecha G, et al. Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients. Blood. 2017;130(15):1535-1542.

Funding
This work was also supported in part by grants and contracts to H-PK from the NIH HHSN2680004 and HL122175 and by funds to JEA from the Fred Hutch. This research was also funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704. H-PK is a Markey Molecular Medicine Investigator and received support as the inaugural recipient of the José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research and the Fred Hutch Endowed Chair for Cell and Gene Therapy. JEA and H-PK are co-inventors on U.S. Provisional Patent Applications #62/491,416 and #62/503,801. "Novel Manufacturing of Gene Corrected Autologous Blood Cells for Gene Therapy." JEA has previously served as a consultant for Rocket Pharmaceuticals. H-PK is an active consultant for Rocket Pharmaceuticals. The other authors declare that they have no competing interests.